The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 21, 2025

Filed:

May. 20, 2021
Applicant:

University of Cincinnati, Cincinnati, OH (US);

Inventors:

Maria Franciszka Czyzyk-Krzeska, Cincinnati, OH (US);

Julio Alberto Landero Figueroa, Cincinnati, OH (US);

Jarek Meller, Cincinnati, OH (US);

David Plas, Cincinnati, OH (US);

Shuchi Gulati, Cincinnati, OH (US);

Bhargav Vemuri, Mason, OH (US);

John Thomas Cunningham, Iv, Maineville, OH (US);

Assignee:

University of Cincinnati, Cincinnati, OH (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2017.12); C12Q 1/6886 (2017.12); G01N 33/574 (2005.12);
U.S. Cl.
CPC ...
C12Q 1/6886 (2012.12); G01N 33/57438 (2012.12); C12Q 2600/118 (2012.12); C12Q 2600/158 (2012.12); G01N 2333/90216 (2012.12);
Abstract

A method of diagnosing the likelihood of recurrence of clear cell renal cell carcinoma is provided. The method involves a) detecting the gene expression signatures of mitochondrial electron transport chain subunits, mitochondrial ribosomal proteins, major histocompatibility complex class II (MHC-II) proteins or combinations thereof in a kidney tumor tissue sample; and b) determining that the subject has an elevated risk of recurrence of clear cell renal cell carcinoma if the gene expression signatures include certain sequences. In another embodiment, the method uses copper levels to diagnose the likelihood of recurrence of clear cell renal cell carcinoma.


Find Patent Forward Citations

Loading…